Prepare for up to a Dozen Humira Biosimilars

November 2022

Up to 12 biosimilars for Humira (adalimumab) are slated to hit the market in 2023...starting with Amjevita in January.

This is a big deal. Humira is approved for several indications...rheumatoid arthritis, plaque psoriasis, Crohn’s, etc.

Plus it’s a top seller...annual revenue is over $20 billion.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Influenza Continue to Save Flu Antivirals for High-Risk Patients
Biosimilars Prepare for up to a Dozen Humira Biosimilars
Anticoagulants Know When to Rely on Warfarin Instead of a DOAC
Infectious Diseases Don’t Jump to Antibiotics for Acute Infectious Diarrhea
Contraceptives Clear Up Confusion About Emergency Contraception
Med Safety Watch for Gallbladder Problems in Patients on GLP-1 Agonists
Cardiology Match the Choice of Calcium Channel Blocker to Your Patient
Statins Know When to Consider Statins for Primary Prevention
Hormone Therapy Answer FAQs About Menopausal Hormone Therapy
Hypernatremia Sort Through Treatments for Hyponatremia
Antibiotics Consider the Best Role for Vancomycin AUC Dosing